ASCO GUIDELINES Bundle

Immune-related Adverse Events CAR T-Cell Therapy

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475467

Contents of this Issue

Navigation

Page 11 of 15

12 Management Table 4. Cytopenias Recommendations Workup/Evaluation: • CBC with differential, peripheral blood smear, reticulocyte count. If abnormalities are detected and further investigation is necessary for a diagnosis, proceed with bone marrow evaluation. Grading Management G1: anemia: LLN – 10.0 g/dL; neutropenia: >1,500 per mm 3 ; thrombocytopenia: >75,000 per mm 3 • Offer supportive care. G2: anemia: <10.0–8.0 g/dL; neutropenia: >1,000 per mm 3 ; thrombocytopenia: >50,000 per mm 3 • Offer supportive care and/or consider corticosteroids. • If improved to ≤G1, taper steroids over 4–6 weeks. G3: anemia: <8.0/dL; neutropenia: >500 per mm 3 ; thrombocytopenia: >25,000 per mm 3 G4: anemia: life-threatening ; neutropenia: <500 per mm3; thrombocytopenia: <25,000 per mm 3 • Critical care support. • Use high-dose methylprednisolone. • Consider growth factor support for neutrophil recovery, per institutional guidelines.

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Immune-related Adverse Events CAR T-Cell Therapy